The global urothelial cancer treatment market is estimated to witness significant growth during the forecast period. The rising frequency of urothelial cancer among middle-aged and older-aged people is driving the market. About 90% of the urothelial cancer patients are older than 55 years and the average age of people are diagnosed with urothelial cancer is 73 years. Due to the growing incidence of urothelial cancer, drug manufacturers are making efforts to develop innovative cancer therapies. Immunotherapy has less toxicity than chemotherapy which makes it more suitable for the elderly population. Immunotherapy shows a rapid and sustained response as compared to chemotherapy. The companies present in the market are focused on developing innovative diagnostic and treatment solutions for urothelial cancer.
Browse the full report description of "Global Urothelial Cancer Treatment Market Size, Share & Trends Analysis Report, by Therapy (Chemotherapy, Immunotherapy, Others) and Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/urothelial-cancer-treatment-market
Immunotherapy, also called biologic therapy. This therapy is intended to boost the natural immune system to fight cancer. Immunotherapy is of two types, local therapy, and systemic therapy. Bacillus Calmette-Guerin (BCG), a standard Immunotherapy drug, used for the treatment of urothelial cancer. Through the catheter, it is directly placed into the bladder. Interferon (Roferon-A, Intron A, Alferon), another type of Immunotherapy it is combined with BCG for the treatment of urothelial cancer. Some of the major drugs used in Immunotherapy are Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi), Nivolumab (Opdivo), Pembrolizumab (Keytruda), and others.
The companies present in the market are focused on developing innovative treatment solutions for urothelial cancer treatment. For instance, in May 2016, the company got FDA approval for its cancer immunotherapy Tecentriq (atezolizumab) for the treatment of a specific type of advanced bladder cancer. Further, in 2017, the FDA granted approval to nivolumab (Opdivo) for the treatment of bladder cancer. This makes nivolumab one of the immune checkpoint inhibitor among 5 inhibitors approved for the treatment of bladder cancer. Such advancement is expected to boost the growth of the global urothelial cancer treatment market in the near future.
Global Urothelial Cancer Treatment Market Segmentation
By Therapy Type
Global Global Urothelial Cancer Treatment Market– Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/urothelial-cancer-treatment-market